Core Insights - Novocure (NVCR) has received approval from Japan's Ministry of Health, Labour and Welfare for reimbursement of Optune Lua under the National Health Insurance program, aimed at adult patients with unresectable, advanced or recurrent Non-Small Cell Lung Cancer (NSCLC) who have shown disease progression after platinum-based chemotherapy [1][2] Company Developments - The approval of Optune Lua is expected to enhance Novocure's growth prospects by increasing patient access to the therapy in Japan, a significant healthcare market [4] - The reimbursement coverage will likely reduce financial barriers for patients and healthcare providers, facilitating the adoption of Novocure's Tumor Treating Fields (TTFields) therapy [4][10] - Currently, Novocure has a market capitalization of $1.48 billion [6] Product Information - Optune Lua is a portable medical device that delivers TTFields, which disrupt cancer cell division through alternating electric fields [8][9] - The therapy is designed to selectively target cancer cells while minimizing effects on healthy cells, leveraging biological differences between the two [9] Market Context - Lung cancer is a leading cause of cancer-related deaths globally, with NSCLC accounting for approximately 85% of all lung cancer cases; around 100,000 new NSCLC cases are diagnosed annually in Japan [11] - The metastatic non-small cell lung cancer market is projected to reach $20.45 billion by 2026, with a compound annual growth rate (CAGR) of 10.5% through 2035, driven by factors such as late-stage diagnosis and advancements in therapies [13] Broader Implications - Beyond lung cancer, TTFields therapy shows potential across various solid tumors, with preclinical studies indicating that it may enhance treatment effects when combined with other therapies [12] - The decision to include Optune Lua in Japan's National Health Insurance program aligns with Novocure's strategy to expand its international oncology market presence and build recurring device-based treatment revenues [4]

Financial Data and Key Metrics Changes - The company generated a record $655 million in net revenues for 2025, representing an 8% increase from 2024 [5][17] - Fourth quarter net revenue was $174 million, also reflecting an 8% year-over-year growth [17] - Adjusted EBITDA was negative $34 million for the full year, with a guidance of -$20 million to break even for 2026 [21][23] Business Line Data and Key Metrics Changes - Optune Lua revenue for the full year was $10.4 million, including $5.8 million from non-small cell lung cancer patients [17] - The company expects contributions from new indications, including Optune Lua and Optune Pax, to be in the range of $15 million to $25 million for 2026 [19][29] Market Data and Key Metrics Changes - Active patient growth in major markets included 10% in Germany, 19% in France, and 29% in Japan, while the U.S. saw a 4% growth [11] - The company anticipates modest contributions from new market launches in Spain, Czechia, and British Columbia [12] Company Strategy and Development Direction - The company aims to drive profitability and has set a goal to reach adjusted EBITDA breakeven in 2026 [23][56] - The recent approval of Optune Pax for locally advanced pancreatic cancer is expected to significantly contribute to long-term growth [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Optune products and the importance of establishing coverage policies with payers [49] - The company is focused on maintaining momentum and achieving regulatory, clinical, and commercial milestones in 2026 [7][55] Other Important Information - The company resolved a Medicare billing issue with CMS, ensuring no negative impact on revenue recognition [18] - Dr. Nicolas Leupin resigned as Chief Medical Officer, and Dr. Uri Weinberg will assume the role, combining scientific and clinical organizations to enhance R&D execution [9] Q&A Session Summary Question: Why is the company providing guidance now? - Management indicated that setting clear expectations for growth is essential as the company matures in the public market [27][28] Question: What are the assumptions behind the revenue guidance? - The guidance includes growth from established GBM markets, new markets, and contributions from new indications [29][30] Question: How will Optune Pax be prescribed based on the approved label? - The company plans to target a highly motivated patient population with limited treatment options, emphasizing the unique value proposition of Optune Pax [39] Question: How much sales force is allocated for Optune Pax? - The existing sales team trained for Optune Lua will lead the Optune Pax launch without adding new headcount [44]

Financial Data and Key Metrics Changes - The company generated a record $655 million in net revenues for 2025, an 8% increase from 2024 [5][17] - Fourth quarter net revenue was $174 million, also reflecting an 8% year-over-year growth [17] - Gross margin for Q4 was 76% and 75% for the full year, down from 79% and 77% in 2024, primarily due to decreased prior period collections in the US and increased costs [19] - The net loss for Q4 was $24 million, with a loss per share of $0.22, and a full-year net loss of $136 million, or $1.22 per share [21] Business Line Data and Key Metrics Changes - Optune Lua revenue for the full year was $10.4 million, including $5.8 million from non-small cell lung cancer patients [17] - The company recognized $3.5 million from Optune Lua claims in Q4, including $2.4 million from non-small cell lung cancer [17] - Research and development costs increased by 19% in Q4 to $61 million, driven by costs related to phase 3 trials [20] Market Data and Key Metrics Changes - Active patient growth in major markets included 10% in Germany, 19% in France, and 29% in Japan, while the US saw a 4% growth [11] - The company expects growth rates to stabilize in the low to mid-single digits as markets mature [11] Company Strategy and Development Direction - The company aims to drive profitable growth and achieve adjusted EBITDA breakeven in 2026 [22] - New product launches are planned for Optune Gio in Spain, Czechia, and British Columbia, and Optune Lua in Japan [8][12] - The approval of Optune Pax for locally advanced pancreatic cancer is expected to significantly contribute to long-term growth [6][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming regulatory, clinical, and commercial milestones for 2026, including the approval of Optune Pax and anticipated data readouts from ongoing trials [6][54] - The company is focused on establishing coverage policies for new indications and believes that the market opportunity for pancreatic cancer is significant [39][49] Other Important Information - The Chief Medical Officer resigned, and the company combined its scientific and clinical organizations to enhance R&D execution [9] - The company resolved a Medicare billing issue with CMS, ensuring no negative impact on revenue recognition [18] Q&A Session Summary Question: Guidance for 2026 - Management indicated that providing guidance now reflects a commitment to returning to steady growth and achieving adjusted EBITDA breakeven [26][27] Question: Optune Gio Revenue Growth - Management clarified that the guidance for low to mid-single digit growth is not a signal of market moderation but reflects the potential for increased patient prescriptions [34] Question: Optune Pax Prescription Strategy - Management emphasized the importance of targeting a highly motivated patient population for Optune Pax and leveraging existing sales teams for the launch [39][44] Question: Sales Force Allocation for Optune Pax - The existing sales team trained for Optune Lua will lead the Optune Pax launch without adding new headcount [44] Question: Revenue Contributions from Optune Pax - Management noted that revenue from Optune Pax will initially lag as coverage policies are established, with expectations for routine coverage taking 1-2 years [49][50]

forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, man ufa cturing developmen ...

Core Viewpoint - Novocure (NVCR) has received FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, ahead of the expected timeline of Q2 2026 [1][2] Company Developments - The FDA approval is based on the successful phase III study, PANOVA-3, which showed that Optune Pax combined with gem/nab-pac significantly improved overall survival compared to gem/nab-pac alone [2][9] - Novocure has other commercialized therapies using Tumor Treating Fields (TTFields), including Optune Gio for glioblastoma multiforme and Optune Lua for metastatic non-small cell lung cancer [3] - The company is also developing therapies for treating metastatic pancreatic cancer and newly diagnosed glioblastoma multiforme [3] Clinical Data - The PANOVA-3 study demonstrated a median overall survival (mOS) of 16.2 months for patients treated with Optune Pax and gem/nab-pac, compared to 14.2 months for those receiving gem/nab-pac alone [8][10] - The one-year survival rate was 68.1% for the Optune Pax group versus 60.2% for the gem/nab-pac group [10] - Additionally, the median time to pain progression improved to 15.2 months with Optune Pax compared to 9.1 months for gem/nab-pac alone [10] Market Potential - The pancreatic cancer market is projected to grow from $3.01 billion to $9.57 billion between 2025 and 2034, at a CAGR of 13.7%, driven by increasing cases and advancements in treatment options [12] - The approval of Optune Pax is expected to enhance Novocure's market prospects, given the limited treatment options currently available for pancreatic cancer [12] Financial Performance - Novocure reported preliminary net revenues of $174.4 million for Q4 and full-year 2025, reflecting an 8% year-over-year increase, with total revenues for the year reaching $655 million [13]

Company Overview - NovoCure (NVCR) is a medtech company that specializes in developing, manufacturing, and selling proprietary Tumor Treating Fields (TTFields) devices aimed at treating solid tumor cancers [1] Product Information - The company currently markets two products, including Optune Gio, which is specifically designed for the treatment of certain types of cancers [1] Investment Perspective - The Stock Research Platform (SRP) is actively screening the market for companies like NovoCure that possess a strong balance sheet, sustainable growth pathways, and valuations that present significant upside potential with limited downside risk [1]

Company Overview - NovoCure (NVCR) is a medtech company that specializes in developing, manufacturing, and selling proprietary Tumor Treating Fields (TTFields) devices aimed at treating solid tumor cancers [1] - The company currently markets two products, including Optune Gio, which is specifically designed for the treatment of certain types of cancers [1] Investment Insights - The Stock Research Platform (SRP) is actively screening the market for companies like NovoCure that possess a strong balance sheet and a sustainable growth pathway, indicating potential for significant upside with limited downside risk [1]

Novocure Q3 2025 earnings Thursday, October 30, 2025 Confidential © 2024 © 2025 NovocuNovocu re GmbH re GmbH 1 forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potent ...

Company Overview - Novocure Limited (NASDAQ: NVCR) develops wearable devices that generate Tumor Treating Fields (TTFields) for the treatment of aggressive cancers [1] - The company has approved devices such as Optune and Optune Gio specifically for treating glioblastoma (GBM) [1] Product Details - Optune Lua is another device developed by Novocure, aimed at assisting in cancer treatment [1]

Company Overview - NovoCure (NVCR) shares increased by 5.3% to close at $18, supported by higher trading volume compared to normal sessions, following an 11.9% decline over the past four weeks [1][2] Product Development - The rise in stock price is linked to growing investor optimism regarding the development and commercialization of Tumor Treating Fields (TTFields) devices, specifically Optune Gio and Optune Lua, which are approved for treating solid tumor cancers [2] Financial Performance - NovoCure is expected to report a quarterly loss of $0.40 per share, reflecting a year-over-year decrease of 29%. Revenue is anticipated to be $152.48 million, representing a 1.4% increase from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - NovoCure holds a Zacks Rank of 2 (Buy) and is part of the Zacks Medical - Biomedical and Genetics industry. In comparison, Kymera Therapeutics, another company in the same industry, saw a 3.5% decline in its stock price, despite a 51.1% return over the past month [5] - Kymera Therapeutics has experienced a 5.8% increase in its consensus EPS estimate over the past month, now projected at -$0.84, which is a 44.8% decrease from the previous year [6]